Compare Mutual Funds
Select a Mutual Fund
Risk | Very High | - |
Rating | 2.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.3 | - |
NAV | ₹30.52 | - |
Fund Started | 20 Jun 2019 | - |
Fund Size | ₹853.63 Cr | - |
Exit Load | Exit load of 1% if redeemed within 30 days. | - |
Risk
Very High
-
Rating
2.0
-
Min SIP Amount
₹100
-
Expense Ratio
2.3
-
NAV
₹30.52
-
Fund Started
20 Jun 2019
-
Fund Size
₹853.63 Cr
-
Exit Load
Exit load of 1% if redeemed within 30 days.
-
1 Year | -0.87% | - |
3 Year | 21.00% | - |
5 Year | 13.86% | - |
1 Year
-0.87%
-
3 Year
21.00%
-
5 Year
13.86%
-
Equity | 97.67% | - |
Cash | 2.33% | - |
Equity
97.67%
-
Cash
2.33%
-
Top 10 Holdings |
| - |
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.47% |
Apollo Hospitals Enterprise Ltd. | 7.30% |
Cipla Ltd. | 6.76% |
Lupin Ltd. | 4.79% |
Abbott India Ltd. | 4.56% |
Torrent Pharmaceuticals Ltd. | 4.47% |
JB Chemicals & Pharmaceuticals Ltd. | 4.31% |
Aurobindo Pharma Ltd. | 4.19% |
Fortis Healthcare Ltd. | 4.07% |
Ajanta Pharma Ltd. | 3.88% |
-
Name | Dhaval Joshi | - |
Start Date | 10 Jun 2024 | - |
Name
Dhaval Joshi
-
Start Date
10 Jun 2024
-
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | - |
Launch Date | 20 Jun 2019 | - |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
-
Launch Date
20 Jun 2019
-